Literature DB >> 4028299

Salivary excretion of 5-fluorouracil. I. Fluctuation of the saliva/plasma concentration ratio and salivary clearance in beagle dogs following bolus intravenous administration.

J Watanabe, Y Hayashi, K Iwamoto, S Ozeki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028299     DOI: 10.1248/cpb.33.1187

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


× No keyword cloud information.
  5 in total

1.  Salivary passage of 5-fluorouracil during continuous infusion.

Authors:  G Milano; A Thyss; J Santini; M Frenay; E Francois; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Regional delivery of model compounds and 5-Fluorouracil to the liver by their application to the liver surface in rats: its implication for clinical use.

Authors:  Koyo Nishida; Rie Fujiwara; Yukinobu Kodama; Shintaro Fumoto; Takahiro Mukai; Mikiro Nakashima; Hitoshi Sasaki; Junzo Nakamura
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

3.  Mandibular and parotid salivary levels of indomethacin following intravenous administration to rabbits.

Authors:  J Watanabe; T Setoyama; K Iwamoto; Y Hayashi; S Ozeki
Journal:  Pharm Res       Date:  1985-07       Impact factor: 4.200

4.  Serial collection method of dog saliva: Effects of different chemical stimulants on behaviour, volume and saliva composition.

Authors:  Juan Pablo Damián; Laura Bengoa; Paula Pessina; Silvia Martínez; Fernando Fumagalli
Journal:  Open Vet J       Date:  2018-07-03

5.  A pilot study of the clinical evidence for the methodology for prevention of oral mucositis during cancer chemotherapy by measuring salivary excretion of 5-fluorouracil.

Authors:  Akiko Kumagai; Shin Iijima; Takayuki Nomiya; Izuru Furuya; Yu Ohashi; Koichi Tsunoda; Kei Onodera; Naoko Tsunoda; Yuko Komatsu; Taifu Hirano
Journal:  BDJ Open       Date:  2018-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.